Some researchers are discussing the idea of building organisms from molecules with reversed structures. An interdisciplinary group says potential consequences include untreatable infections and irreversible ecosystem disruption.

Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria.

Ionpath, a leader in high-definition spatial proteomics, today announced the launch of MIBIslide™ Blue, a groundbreaking advancement in multimodal ima

Using a gene-screening method they created, Stanford Medicine researchers may have discovered why an effective chemotherapy damages heart cells-and they have identified a drug that could keep the...

A three-decade series of coincidences will likely help doctors treat narcolepsy — and possibly prevent opioid addiction — and could lead to a Nobel Prize for two scientists who never collaborated.

Stanford’s Chad Weldy, MD, PhD, investigates RNA editing's role in heart disease, offering potential insights into genetic factors behind coronary artery disease.

Why do some people develop severe flu symptoms? A study points the finger at an unsung portion of the antibodies our immune systems generate to fend off invading pathogens.

The fellowship recognizes PhD students and their faculty advisers who are committed to advancing equity and inclusion in the sciences.

CAR-T cells show promise against pediatric diffuse midline gliomas, brain and spinal cord tumors that are among the deadliest cancers, a Stanford Medicine trial found.

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells-;a type of cancer immunotherapy-;that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.

Levy, the director of the Stanford Cancer Institute, has received numerous awards for groundbreaking discoveries on cancer treatment.

The Biophysical Society is pleased to announce the recipients of its 2025 Society Awards. These awards are very competitive in nature and are intended to recognize Society members for excellence in biophysics. The winners will be honored at the Society’s 69th Annual Meeting being held in Los Angeles, California from February 15-19, 2025.

Known for its world renowned study of mice to understand the effects of disease, McLaughlin Research Institute will brand itself as the Weissman-Hood Institute.

The Stanford biophysicist thinks that understanding the mechanics of cell movement could allow scientists to manipulate immune cells.

A hallmark of this cellular engineer’s efforts is communication—among biological systems and with the next generation of scientists

The leaves are starting to change, and cooler temperatures are on the horizon. The cozy fall days ahead unfortunately also mean sickness.

Professor of Medicine Ronald Levy M.D. '68 discussed the impact of the discovery of Rituxan and how further advances in immunotherapy can improve patient outcomes.

The company's oversubscribed $60 million financing round brings its total Series A funding to $90 million.

Time marches on predictably, but biological aging is anything but constant, according to a new Stanford Medicine study.

The US Food and Drug Administration approved an Investigational New Drug application for a g-NK cell therapy in multiple sclerosis (MS).

Researchers at Stanford Engineering have developed a new vaccine additive that creates stronger, tunable immune responses.

A protein called Meteorin-like (METRNL) in the tumor microenvironment saps energy from T cells, thereby severely limiting their ability to fight cancer.

The company's oversubscribed $60 million financing round brings its total Series A funding to $90 million.

The institute’s purpose is to understand the human immune system at multiple levels — molecular, genetic and cellular — and to harness this understanding to prevent and treat disease.

The Parker Institute for Cancer Immunotherapy (PICI) today announced the appointments of Ansu Satpathy, MD, PhD, Julia Carnevale, MD, and Saar Gill, M

aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain...

Genomics and technology development expert Lars Steinmetz now leads Stanford Medicine’s genetics department.

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.

Three structural biologists, recognized for their groundbreaking research and new insights into the immune system, are the first recipients of the Max Cooper Prize in Immunology. The prize is named for the renowned immunologist at Emory.

Tr1X reported that the first patient has cleared the trial’s safety period successfully, having experienced no serious adverse events.

CAR-T cell therapy helps some with intractable lymphoma, but those who relapse have few options. Modifying the therapy's molecular target improved response.

A method that combines a large language model with data about a protein’s 3D shape could make it quicker and easier to develop medications.

The company announced $6.5M in seed funding to develop a multi-targeted platform that exploits highly expressed markers on solid tumors.

Curiox Biosystems is pleased to announce the establishment of the Curiox Innovation Center for the Curiox C-FREE™ Pluto LT System at the Human Immune Monitoring Center (HIMC) at Stanford University.

A single-center study found that second tumors had occurred in 25 of 724 patients during 15 months of follow-up after receipt of CAR T-cell therapy, including one fatal case of T-cell lymphoma.

In a session presented at the 2024 Heart in Diabetes Conference, researchers discussed the abilities of continuous glucose monitoring (CGM) to capture lifestyle data and improve mortality rates.

Garcia was recognized for his research into the way molecules bind to one another and its implications for safer and more effective treatments.

After 5 years with COVID-19, health experts say there is still much to learn about the virus that causes the disease. At the height of the pandemic, hospitals were overwhelmed with patients with severe cases of the respiratory virus including life-threatening complications. It was believed that a certain type of lung cell made some people more susceptible to severe infection but now that is no longer the case. KTVU's Heather Holmes speaks with Stanford scientists Catherine Blish and Mark Krasnow about their critical new research that found a different suspected source of vulnerability.

A previously overlooked type of immune cell allows SARS-CoV-2 to proliferate, Stanford Medicine scientists have found. The discovery has important implications for preventing severe COVID-19.

SAN DIEGO, CA, USA I April 10, 2024 I Tr1X, Inc., an autoimmune and inflammatory disease cell therapy company focused on the development of novel

by Michael Howell Feeling old and especially vulnerable in the face of the many variations of Flu and RSVP viruses going around? There is good reason to be concerned. Recent […]

Research suggested that EBV is the primary cause of MS. What are the clinical implications, and could this transform treatment and prevention of this neurodegenerative condition?

Those with aging immune systems struggle to fight off novel viruses and respond weakly to vaccination. Stanford Medicine researchers were able to revitalize the immune system in mice.

On this episode of FYI, hosts Nemo Marjanovic and Charles Roberts speak with Professor Dr. Michael Snyder, a leading figure in genomics and personalized medicine.

None of the treatments designed to fight Camille's acute lymphocytic leukemia worked, until an innovative stem cell transplant at Stanford.

Trillions of bacteria inhabiting our bodies -- collectively known as the microbiome -- are as unique to an individual as their fingerprint.

The road to developing monoclonal antibodies for effectively targeting cancer was paved with tenacity, passion, and strokes of luck.

Leukemia - CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results

None of the treatments designed to fight Camille's acute lymphocytic leukemia worked, until an innovative stem cell transplant at Stanford.

A molecular “snapshot” of a protein can be critical to understanding its function. Scientists at Stanford and NYU have published and investigated a new structure of the protein LAG-3 which could enable the development of new cancer treatments.

Statistics expert Julia Salzman returned to biology and has married her two areas of expertise to design a new form of genomics analysis.

The ultimate goal: a vaccine with coverage so broad it can protect against viruses never before encountered.

The ultimate goal: a vaccine with coverage so broad it can protect against viruses never before encountered.

Stanford Medicine researchers are designing vaccines that might protect people from not merely individual viral strains but broad ranges of them. The ultimate goal: a vaccine with coverage so broad it can protect against viruses never before encountered.

Stabl selects sparse and reliable biomarker candidates from predictive models.